Show simple item record

dc.contributor.authorHernández Fernández, Carlos Pelayo
dc.contributor.authorBorrego Hernando, Leopoldo
dc.contributor.authorMercader García, Pedro
dc.contributor.authorGiménez Arnau, Anna María
dc.contributor.authorSánchez Pérez, Javier
dc.contributor.authorSilvestre Salvador, Juan Francisco
dc.contributor.authorGonzález Pérez, Ricardo
dc.contributor.authorSanz Sánchez, Tatiana
dc.contributor.authorSánchez Gilo, Araceli
dc.contributor.authorMelé Ninot, Gemma
dc.contributor.authorZaragoza Ninet, Violeta
dc.contributor.authorMiquel Miquel, Francisco Javier
dc.contributor.authorCarrascosa Carrillo, José Manuel
dc.contributor.authorCórdoba Guijarro, Susana
dc.contributor.authorGatica Ortega, María Elena
dc.contributor.authorRuiz González, Inmaculada
dc.contributor.authorSerra Baldrich, Esther
dc.contributor.authorTous Romero, Fátima
dc.contributor.authorRodríguez Serna, Mercedes
dc.contributor.authorPastor Nieto, María Antonia
dc.contributor.authorPérez Feal, Patricia
dc.contributor.authorHervella Garcés, Marcos
dc.contributor.authorDe Vega Martínez, Marina
dc.contributor.authorGarcía Doval, Ignacio
dc.date.accessioned2023-05-04T16:58:43Z
dc.date.available2023-05-04T16:58:43Z
dc.date.issued2023-03
dc.identifier.citationContact Dermatitis 88(3) : 212-219 (2023)es_ES
dc.identifier.issn0105-1873
dc.identifier.issn1600-0536
dc.identifier.urihttp://hdl.handle.net/10810/61037
dc.description.abstractBackground: Current frequency and risk factors for sensitization to methylisothiazolinone (MI), methylchloroisothiazolinone/methylisothiazolinone (MCI/MI), benzisothiazolinone (BIT) and octylisothiazolinone (OIT) in Spain are not well known. Objectives: To study the frequency of sensitization, risk factors and simultaneous sensitization between the four isothiazolinones. Materials and Methods: We analysed all 2019-2021 consecutive patients patch-tested with MI (0.2% aq.), MCI/MI (0.02% aq.), BIT (0.1% pet.) and OIT (0.1% pet) within the Spanish Contact Dermatitis Registry (REIDAC). Results: A total of 2511 patients were analysed. Frequencies of sensitization were: any isothiazolinone 15.7%, MI 6.8%, MCI/MI 4.8%, BIT 3.5% and OIT 0.5%. MI and MCI/MI sensitization was associated with being occupationally active, hand dermatitis, detergents and age over 40. BIT sensitization was associated with leg dermatitis and age over 40. About one in nine MI-positive patients were positive to BIT, whereas one in five BIT-positive patients were positive to MI. Conclusions: Sensitization to MI, MCI/MI and BIT is still common in Spain, while sensitization to OIT is rare. Currently, sensitization to MI and MCI/MI seems to be occupationally related. Although its origin is unknown, sensitization to BIT is more frequent in patients aged over 40 years. Simultaneous sensitization between MI and BIT is uncommon.es_ES
dc.description.sponsorshipThe Spanish Registry of Contact Dermatitis (REIDAC) is promoted by the Fundación Piel Sana (Academia Española de Dermatología y Venereología), which has received financial support from the Spanish Medicines and Health Products Agency (Agencia Española de Medicamentos y Productos Sanitarios. https://www.boe.es/boe/dias/2022/04/11/pdfs/BOE-A-2022-5975.pdf) and Sanofi. The funders were not involved in the design and conduct of the study, collection, management, analysis and interpretation of data, preparation, review, approval of the manuscript, or decision to submit the manuscript for publication.es_ES
dc.language.isoenges_ES
dc.publisherWileyes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectbenzisothiazolinonees_ES
dc.subjectcontact dermatitises_ES
dc.subjectmethylchloroisothiazolinone/methylisothiazolinonees_ES
dc.subjectmethylisothiazolinonees_ES
dc.subjectoctylisothiazolinonees_ES
dc.subjectpatch testses_ES
dc.subjectSpaines_ES
dc.subjectstandard serieses_ES
dc.titleSensitization to isothiazolinones in the Spanish Contact Dermatitis Registry (REIDAC): 2019–2021 epidemiological situationes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder© 2022 The Authors. Contact Dermatitis published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.es_ES
dc.rights.holderAtribución-NoComercial-SinDerivadas 3.0 España*
dc.relation.publisherversionhttps://onlinelibrary.wiley.com/doi/10.1111/cod.14251es_ES
dc.identifier.doi10.1111/cod.14251
dc.departamentoesDermatología, oftalmología y otorrinolaringologíaes_ES
dc.departamentoeuDermatologia, oftalmologia eta otorrinolaringologiaes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2022 The Authors. Contact Dermatitis published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Except where otherwise noted, this item's license is described as © 2022 The Authors. Contact Dermatitis published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.